<?xml version="1.0" encoding="utf-8"?>
<export-example>
  <doc>
    <id>35195</id>
    <completedYear/>
    <publishedYear>2024</publishedYear>
    <thesisYearAccepted/>
    <language>eng</language>
    <pageFirst>1</pageFirst>
    <pageLast>11</pageLast>
    <pageNumber>11</pageNumber>
    <edition/>
    <issue>1</issue>
    <volume>16</volume>
    <type>articler</type>
    <publisherName>Springer Science and Business Media LLC</publisherName>
    <publisherPlace/>
    <creatingCorporation/>
    <contributingCorporation/>
    <belongsToBibliography>0</belongsToBibliography>
    <completedDate>2025-01-15</completedDate>
    <publishedDate>--</publishedDate>
    <thesisDateAccepted>--</thesisDateAccepted>
    <title language="eng">Fecal glycoprotein 2 is a marker of gut microbiota dysbiosis and systemic inflammation</title>
    <abstract language="eng">Background&#13;
autoantigenic glycoprotein 2 (GP2) is an important component of the innate immune system which originates from the exocrine pancreas as well as from the small intestines. The relationship of GP2 with the intestinal microbiome as well as the systemic implications of increased fecal GP2 levels are, however, still unclear. Therefore, fecal samples from 2,812 individuals of the Study of Health in Pomerania (SHIP) were collected to determine GP2 levels (enzyme-linked immunosorbent assay) and gut microbiota profiles (16 S rRNA gene sequencing). These data were correlated and associated with highly standardised and comprehensive phenotypic data of the study participants.&#13;
 Results&#13;
Fecal GP2 levels were increased in individuals with higher body mass index and smokers, whereas lower levels were found in case of preserved exocrine pancreatic function, female sex or a healthier diet. Moreover, higher GP2 levels were associated with increased serum levels of high-sensitivity C-reactive protein, loss of gut microbial diversity and an increase of potentially detrimental bacteria (Streptococcus, Haemophilus, Clostridium XIVa, or Collinsella). At the same time, predicted microbial pathways for the biosynthesis of beneficial short-chain fatty acids or lactic acid were depleted in individuals with high fecal GP2. Of note, GP2 exhibited a stronger association to overall microbiome variation than calprotectin.&#13;
Conclusion&#13;
 Fecal GP2 is a biomarker of gut microbiota dysbiosis and associated with increased systemic inflammation. The intestines may be more important as origin for GP2 than pancreatic acinar cells. Future studies need to investigate the potential clinical value in disease specific patient cohorts.</abstract>
    <parentTitle language="eng">Gut Pathogens</parentTitle>
    <identifier type="doi">10.1186/s13099-024-00657-1</identifier>
    <identifier type="issn">1757-4749</identifier>
    <enrichment key="opus_doi_flag">true</enrichment>
    <enrichment key="opus_doi_json">{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T21:10:14Z","timestamp":1729372214962,"version":"3.27.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T00:00:00Z","timestamp":1729296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T00:00:00Z","timestamp":1729296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsmedizin Greifswald"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gut Pathog"],"abstract":"&lt;jats:title&gt;Abstract&lt;\/jats:title&gt;&lt;jats:sec&gt;\n                &lt;jats:title&gt;Background&lt;\/jats:title&gt;\n                &lt;jats:p&gt;Antimicrobial autoantigenic glycoprotein 2 (GP2) is an important component of the innate immune system which originates from the exocrine pancreas as well as from the small intestines. The relationship of GP2 with the intestinal microbiome as well as the systemic implications of increased fecal GP2 levels are, however, still unclear. Therefore, fecal samples from 2,812 individuals of the Study of Health in Pomerania (SHIP) were collected to determine GP2 levels (enzyme-linked immunosorbent assay) and gut microbiota profiles (16\u00a0S rRNA gene sequencing). These data were correlated and associated with highly standardised and comprehensive phenotypic data of the study participants.&lt;\/jats:p&gt;\n              &lt;\/jats:sec&gt;&lt;jats:sec&gt;\n                &lt;jats:title&gt;Results&lt;\/jats:title&gt;\n                &lt;jats:p&gt;Fecal GP2 levels were increased in individuals with higher body mass index and smokers, whereas lower levels were found in case of preserved exocrine pancreatic function, female sex or a healthier diet. Moreover, higher GP2 levels were associated with increased serum levels of high-sensitivity C-reactive protein, loss of gut microbial diversity and an increase of potentially detrimental bacteria (&lt;jats:italic&gt;Streptococcus&lt;\/jats:italic&gt;, &lt;jats:italic&gt;Haemophilus&lt;\/jats:italic&gt;, &lt;jats:italic&gt;Clostridium XIVa&lt;\/jats:italic&gt;, or &lt;jats:italic&gt;Collinsella&lt;\/jats:italic&gt;). At the same time, predicted microbial pathways for the biosynthesis of beneficial short-chain fatty acids or lactic acid were depleted in individuals with high fecal GP2. Of note, GP2 exhibited a stronger association to overall microbiome variation than calprotectin.&lt;\/jats:p&gt;\n              &lt;\/jats:sec&gt;&lt;jats:sec&gt;\n                &lt;jats:title&gt;Conclusion&lt;\/jats:title&gt;\n                &lt;jats:p&gt;Fecal GP2 is a biomarker of gut microbiota dysbiosis and associated with increased systemic inflammation. The intestines may be more important as origin for GP2 than pancreatic acinar cells. Future studies need to investigate the potential clinical value in disease specific patient cohorts.&lt;\/jats:p&gt;\n              &lt;\/jats:sec&gt;","DOI":"10.1186\/s13099-024-00657-1","type":"journal-article","created":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T08:02:11Z","timestamp":1729324931000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fecal glycoprotein 2 is a marker of gut microbiota dysbiosis and systemic inflammation"],"prefix":"10.1186","volume":"16","author":[{"given":"Fabian","family":"Frost","sequence":"first","affiliation":[]},{"given":"Stefan","family":"Weiss","sequence":"additional","affiliation":[]},{"given":"Johannes","family":"Hertel","sequence":"additional","affiliation":[]},{"given":"Malte","family":"R\u00fchlemann","sequence":"additional","affiliation":[]},{"given":"Corinna","family":"Bang","sequence":"additional","affiliation":[]},{"given":"Andre","family":"Franke","sequence":"additional","affiliation":[]},{"given":"Matthias","family":"Nauck","sequence":"additional","affiliation":[]},{"given":"Marcus","family":"D\u00f6rr","sequence":"additional","affiliation":[]},{"given":"Henry","family":"V\u00f6lzke","sequence":"additional","affiliation":[]},{"given":"Dirk","family":"Roggenbuck","sequence":"additional","affiliation":[]},{"given":"Peter","family":"Schierack","sequence":"additional","affiliation":[]},{"given":"Uwe","family":"V\u00f6lker","sequence":"additional","affiliation":[]},{"given":"Georg","family":"Homuth","sequence":"additional","affiliation":[]},{"given":"Ali A.","family":"Aghdassi","sequence":"additional","affiliation":[]},{"given":"Matthias","family":"Sendler","sequence":"additional","affiliation":[]},{"given":"Markus M.","family":"Lerch","sequence":"additional","affiliation":[]},{"given":"Frank U.","family":"Weiss","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2024,10,19]]},"reference":[{"issue":"1","key":"657_CR1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41579-020-0433-9","volume":"19","author":"Y Fan","year":"2021","unstructured":"Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. Nat Rev Microbiol. 2021;19(1):55\u201371.","journal-title":"Nat Rev Microbiol"},{"issue":"6285","key":"657_CR2","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1126\/science.aad3369","volume":"352","author":"A Zhernakova","year":"2016","unstructured":"Zhernakova A, Kurilshikov A, Bonder MJ, Tigchelaar EF, Schirmer M, Vatanen T, et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science. 2016;352(6285):565\u20139.","journal-title":"Science"},{"issue":"4","key":"657_CR3","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1053\/j.gastro.2018.10.047","volume":"156","author":"F Frost","year":"2019","unstructured":"Frost F, Kacprowski T, R\u00fchlemann M, B\u00fclow R, K\u00fchn J-P, Franke A, et al. Impaired exocrine pancreatic function associates with changes in intestinal microbiota composition and diversity. Gastroenterology. 2019;156(4):1010\u20135.","journal-title":"Gastroenterology"},{"issue":"5","key":"657_CR4","doi-asserted-by":"publisher","first-page":"e2290","DOI":"10.1210\/clinem\/dgaa961","volume":"106","author":"M Pietzner","year":"2021","unstructured":"Pietzner M, Budde K, R\u00fchlemann M, V\u00f6lzke H, Homuth G, Weiss FU, et al. Exocrine pancreatic function modulates plasma metabolites through changes in gut microbiota composition. J Clin Endocrinol Metab. 2021;106(5):e2290\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"657_CR5","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1136\/gutjnl-2020-322753","volume":"70","author":"F Frost","year":"2021","unstructured":"Frost F, Kacprowski T, R\u00fchlemann M, Pietzner M, Bang C, Franke A, et al. Long-term instability of the intestinal microbiome is associated with metabolic liver disease, low microbiota diversity, diabetes mellitus and impaired exocrine pancreatic function. Gut. 2021;70(3):522\u201330.","journal-title":"Gut"},{"issue":"1","key":"657_CR6","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s12934-020-01482-2","volume":"19","author":"S Ritz","year":"2020","unstructured":"Ritz S, Hahn D, Wami HT, Tegelkamp K, Dobrindt U, Schnekenburger J. Gut microbiome as a response marker for pancreatic enzyme replacement therapy in a porcine model of exocrine pancreas insufficiency. Microb Cell Fact. 2020;19(1):221.","journal-title":"Microb Cell Fact"},{"issue":"7270","key":"657_CR7","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nature08529","volume":"462","author":"K Hase","year":"2009","unstructured":"Hase K, Kawano K, Nochi T, Pontes GS, Fukuda S, Ebisawa M, et al. Uptake through glycoprotein 2 of FimH(+) bacteria by M cells initiates mucosal immune response. Nature. 2009;462(7270):226\u201330.","journal-title":"Nature"},{"issue":"6","key":"657_CR8","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.4049\/jimmunol.1103190","volume":"189","author":"L Werner","year":"2012","unstructured":"Werner L, Paclik D, Fritz C, Reinhold D, Roggenbuck D, Sturm A. Identification of pancreatic glycoprotein 2 as an endogenous immunomodulator of innate and adaptive immune responses. J Immunol. 2012;189(6):2774\u201383.","journal-title":"J Immunol"},{"issue":"5","key":"657_CR9","doi-asserted-by":"publisher","first-page":"e0227921","DOI":"10.1128\/aem.02279-21","volume":"88","author":"C Bartlitz","year":"2022","unstructured":"Bartlitz C, Kolenda R, Chilimoniuk J, Grzymaj\u0142o K, R\u00f6diger S, Bauerfeind R, et al. Adhesion of Enteropathogenic, Enterotoxigenic, and Commensal Escherichia coli to the Major Zymogen Granule Membrane Glycoprotein 2. Appl Environ Microbiol. 2022;88(5):e0227921.","journal-title":"Appl Environ Microbiol"},{"issue":"12","key":"657_CR10","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1093\/ibd\/izaa069","volume":"26","author":"S Derer","year":"2020","unstructured":"Derer S, Brethack A-K, Pietsch C, Jendrek ST, Nitzsche T, Bokemeyer A, et al. Inflammatory bowel disease-associated GP2 autoantibodies inhibit mucosal Immune response to adherent-invasive Bacteria. Inflamm Bowel Dis. 2020;26(12):1856\u201368.","journal-title":"Inflamm Bowel Dis"},{"key":"657_CR11","doi-asserted-by":"publisher","first-page":"109214","DOI":"10.1016\/j.clim.2022.109214","volume":"247","author":"D Roggenbuck","year":"2023","unstructured":"Roggenbuck D, Goihl A, Sowa M, Lopens S, R\u00f6diger S, Schierack P, et al. Human glycoprotein-2 expressed in Brunner glands - a putative autoimmune target and link between Crohn\u2019s and coeliac disease. Clin Immunol. 2023;247:109214.","journal-title":"Clin Immunol"},{"issue":"12","key":"657_CR12","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1136\/gut.2008.162495","volume":"58","author":"D Roggenbuck","year":"2009","unstructured":"Roggenbuck D, Hausdorf G, Martinez-Gamboa L, Reinhold D, B\u00fcttner T, Jungblut PR, et al. Identification of GP2, the major zymogen granule membrane glycoprotein, as the autoantigen of pancreatic antibodies in Crohn\u2019s disease. Gut. 2009;58(12):1620\u20138.","journal-title":"Gut"},{"issue":"2","key":"657_CR13","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/apt.16153","volume":"53","author":"E Wunsch","year":"2021","unstructured":"Wunsch E, Norman GL, Milkiewicz M, Krawczyk M, Bentow C, Shums Z, et al. Anti-glycoprotein 2 (anti-GP2) IgA and anti-neutrophil cytoplasmic antibodies to serine proteinase 3 (PR3-ANCA): antibodies to predict severe disease, poor survival and cholangiocarcinoma in primary sclerosing cholangitis. Aliment Pharmacol Ther. 2021;53(2):302\u201313.","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"657_CR14","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1097\/MIB.0000000000000936","volume":"22","author":"F Degenhardt","year":"2016","unstructured":"Degenhardt F, Dirmeier A, Lopez R, Lang S, Kunst C, Roggenbuck D, et al. Serologic Anti-GP2 antibodies are Associated with genetic polymorphisms, fibrostenosis, and need for Surgical Resection in Crohn\u2019s Disease. Inflamm Bowel Dis. 2016;22(11):2648\u201357.","journal-title":"Inflamm Bowel Dis"},{"key":"657_CR15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/bs.acc.2016.06.002","volume":"77","author":"D Roggenbuck","year":"2016","unstructured":"Roggenbuck D, Reinhold D, Baumgart DC, Schierack P, Conrad K, Laass MW. Autoimmunity in Crohn\u2019s Disease-A putative stratification factor of the clinical phenotype. Adv Clin Chem. 2016;77:77\u2013101.","journal-title":"Adv Clin Chem"},{"issue":"11\u201312","key":"657_CR16","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1111\/apt.15034","volume":"48","author":"D Cummings","year":"2018","unstructured":"Cummings D, Cruise M, Lopez R, Roggenbuck D, Jairath V, Wang Y, et al. Loss of tolerance to glycoprotein 2 isoforms 1 and 4 is associated with Crohn\u2019s disease of the pouch. Aliment Pharmacol Ther. 2018;48(11\u201312):1251\u20139.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"657_CR17","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/s41467-021-21277-2","volume":"12","author":"Y Kurashima","year":"2021","unstructured":"Kurashima Y, Kigoshi T, Murasaki S, Arai F, Shimada K, Seki N, et al. Pancreatic glycoprotein 2 is a first line of defense for mucosal protection in intestinal inflammation. Nat Commun. 2021;12(1):1067.","journal-title":"Nat Commun"},{"issue":"1","key":"657_CR18","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1136\/gutjnl-2016-311739","volume":"66","author":"ST Jendrek","year":"2017","unstructured":"Jendrek ST, Gotthardt D, Nitzsche T, Widmann L, Korf T, Michaels MA, et al. Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis. Gut. 2017;66(1):137\u201344.","journal-title":"Gut"},{"issue":"10","key":"657_CR19","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1136\/gutjnl-2015-311004","volume":"65","author":"J Sabino","year":"2016","unstructured":"Sabino J, Vieira-Silva S, Machiels K, Joossens M, Falony G, Ballet V, et al. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD. Gut. 2016;65(10):1681\u20139.","journal-title":"Gut"},{"key":"657_CR20","doi-asserted-by":"crossref","unstructured":"V\u00f6lzke H, Sch\u00f6ssow J, Schmidt CO, J\u00fcrgens C, Richter A, Werner A et al. Cohort Profile Update: the study of Health in Pomerania (SHIP). Int J Epidemiol 2022;51(6):372\u2013383.","DOI":"10.1093\/ije\/dyac034"},{"issue":"2","key":"657_CR21","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1093\/ije\/dyp394","volume":"40","author":"H V\u00f6lzke","year":"2011","unstructured":"V\u00f6lzke H, Alte D, Schmidt CO, Radke D, Lorbeer R, Friedrich N, et al. Cohort profile: the study of health in Pomerania. Int J Epidemiol. 2011;40(2):294\u2013307.","journal-title":"Int J Epidemiol"},{"issue":"6","key":"657_CR22","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1515\/cclm-2016-0797","volume":"55","author":"D Roggenbuck","year":"2017","unstructured":"Roggenbuck D, Goihl A, Hanack K, Holzl\u00f6hner P, Hentschel C, Veiczi M, et al. Serological diagnosis and prognosis of severe acute pancreatitis by analysis of serum glycoprotein 2. Clin Chem Lab Med. 2017;55(6):854\u201364.","journal-title":"Clin Chem Lab Med"},{"issue":"7","key":"657_CR23","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nmeth.3869","volume":"13","author":"BJ Callahan","year":"2016","unstructured":"Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJA, Holmes SP. DADA2: high-resolution sample inference from Illumina amplicon data. Nat Methods. 2016;13(7):581\u20133.","journal-title":"Nat Methods"},{"issue":"1","key":"657_CR24","doi-asserted-by":"publisher","first-page":"6677","DOI":"10.1038\/s41598-021-86247-6","volume":"11","author":"F Frost","year":"2021","unstructured":"Frost F, Kacprowski T, R\u00fchlemann M, Weiss S, Bang C, Franke A, et al. Carrying asymptomatic gallstones is not associated with changes in intestinal microbiota composition and diversity but cholecystectomy with significant dysbiosis. Sci Rep. 2021;11(1):6677.","journal-title":"Sci Rep"},{"issue":"6","key":"657_CR25","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/s41587-020-0548-6","volume":"38","author":"GM Douglas","year":"2020","unstructured":"Douglas GM, Maffei VJ, Zaneveld JR, Yurgel SN, Brown JR, Taylor CM, et al. PICRUSt2 for prediction of metagenome functions. Nat Biotechnol. 2020;38(6):685\u20138.","journal-title":"Nat Biotechnol"},{"issue":"9","key":"657_CR26","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","journal-title":"Ann Intern Med"},{"issue":"12","key":"657_CR27","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1161\/01.STR.0000038422.57919.7F","volume":"33","author":"J Luedemann","year":"2002","unstructured":"Luedemann J, Schminke U, Berger K, Piek M, Willich SN, D\u00f6ring A, et al. Association between behavior-dependent cardiovascular risk factors and asymptomatic carotid atherosclerosis in a general population. Stroke. 2002;33(12):2929\u201335.","journal-title":"Stroke"},{"issue":"3","key":"657_CR28","first-page":"234","volume":"37","author":"G Winkler","year":"1998","unstructured":"Winkler G, D\u00f6ring A. Validation of a short qualitative food frequency list used in several German large scale surveys. Z Ernahrungswiss. 1998;37(3):234\u201341.","journal-title":"Z Ernahrungswiss"},{"key":"657_CR29","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing. https:\/\/www.R-project.org\/ 2020."},{"key":"657_CR30","unstructured":"Wickham H. Ggplot2: Elegrant graphics for data analysis \/ Hadley Wickham; with contributions by Carson Sievert. Second edition. Switzerland: Springer; 2016. (Use R!)."},{"key":"657_CR31","unstructured":"Oksanen J, Blanchet FG, Friendly M, Kindt R, Legendre P, McGlinn D et al. vegan: Community Ecology Package. R package version 2.5-6. https:\/\/CRAN.R-project.org\/package=vegan 2019."},{"issue":"10","key":"657_CR32","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1136\/gutjnl-2021-324855","volume":"70","author":"A Jukic","year":"2021","unstructured":"Jukic A, Bakiri L, Wagner EF, Tilg H, Adolph TE. Calprotectin: from biomarker to biological function. Gut. 2021;70(10):1978\u201388.","journal-title":"Gut"},{"issue":"7","key":"657_CR33","doi-asserted-by":"publisher","first-page":"4257","DOI":"10.1016\/S0021-9258(20)64315-0","volume":"266","author":"TC Hoops","year":"1991","unstructured":"Hoops TC, Rindler MJ. Isolation of the cDNA encoding glycoprotein-2 (GP-2), the major zymogen granule membrane protein. Homology to uromodulin\/Tamm-Horsfall protein. J Biol Chem. 1991;266(7):4257\u201363.","journal-title":"J Biol Chem"},{"issue":"19","key":"657_CR34","doi-asserted-by":"publisher","first-page":"7317","DOI":"10.1073\/pnas.85.19.7317","volume":"85","author":"RL Coppel","year":"1988","unstructured":"Coppel RL, McNeilage LJ, Surh CD, van de Water J, Spithill TW, Whittingham S, et al. Primary structure of the human M2 mitochondrial autoantigen of primary biliary cirrhosis: dihydrolipoamide acetyltransferase. Proc Natl Acad Sci U S A. 1988;85(19):7317\u201321.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"657_CR35","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1053\/j.gastro.2020.12.058","volume":"160","author":"M Kummen","year":"2021","unstructured":"Kummen M, Thingholm LB, R\u00fchlemann MC, Holm K, Hansen SH, Moitinho-Silva L, et al. Altered gut microbial metabolism of essential nutrients in primary sclerosing Cholangitis. Gastroenterology. 2021;160(5):1784\u2013e17980.","journal-title":"Gastroenterology"},{"issue":"7","key":"657_CR36","doi-asserted-by":"publisher","first-page":"e0219489","DOI":"10.1371\/journal.pone.0219489","volume":"14","author":"F Frost","year":"2019","unstructured":"Frost F, Storck LJ, Kacprowski T, G\u00e4rtner S, R\u00fchlemann M, Bang C, et al. A structured weight loss program increases gut microbiota phylogenetic diversity and reduces levels of Collinsella in obese type 2 diabetics: a pilot study. PLoS ONE. 2019;14(7):e0219489.","journal-title":"PLoS ONE"},{"issue":"3","key":"657_CR37","first-page":"1","volume":"2","author":"SM Lambeth","year":"2015","unstructured":"Lambeth SM, Carson T, Lowe J, Ramaraj T, Leff JW, Luo L, et al. Composition, diversity and abundance of gut microbiome in Prediabetes and Type 2 diabetes. J Diabetes Obes. 2015;2(3):1\u20137.","journal-title":"J Diabetes Obes"},{"key":"657_CR38","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3389\/fimmu.2019.00277","volume":"10","author":"D Parada Venegas","year":"2019","unstructured":"Parada Venegas D, La Fuente MK, Landskron G, Gonz\u00e1lez MJ, Quera R, Dijkstra G, et al. Short chain fatty acids (SCFAs)-Mediated gut epithelial and Immune Regulation and its relevance for inflammatory Bowel diseases. Front Immunol. 2019;10:277.","journal-title":"Front Immunol"},{"issue":"6145","key":"657_CR39","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1126\/science.1241165","volume":"341","author":"PM Smith","year":"2013","unstructured":"Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly-Y M, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science. 2013;341(6145):569\u201373.","journal-title":"Science"},{"issue":"6","key":"657_CR40","doi-asserted-by":"publisher","first-page":"e1700572","DOI":"10.1002\/mnfr.201700572","volume":"62","author":"C Ren","year":"2018","unstructured":"Ren C, Dokter-Fokkens J, Figueroa Lozano S, Zhang Q, de Haan BJ, Zhang H, et al. Lactic acid Bacteria may impact intestinal barrier function by modulating Goblet cells. Mol Nutr Food Res. 2018;62(6):e1700572.","journal-title":"Mol Nutr Food Res"},{"issue":"1","key":"657_CR41","doi-asserted-by":"publisher","first-page":"50","DOI":"10.15420\/ecr.2018.33.1","volume":"14","author":"S Tsalamandris","year":"2019","unstructured":"Tsalamandris S, Antonopoulos AS, Oikonomou E, Papamikroulis G-A, Vogiatzi G, Papaioannou S, et al. The role of inflammation in diabetes: current concepts and future perspectives. Eur Cardiol. 2019;14(1):50\u20139.","journal-title":"Eur Cardiol"},{"issue":"5","key":"657_CR42","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.jacc.2013.05.016","volume":"62","author":"O Yousuf","year":"2013","unstructured":"Yousuf O, Mohanty BD, Martin SS, Joshi PH, Blaha MJ, Nasir K, et al. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link? J Am Coll Cardiol. 2013;62(5):397\u2013408.","journal-title":"J Am Coll Cardiol"},{"issue":"7464","key":"657_CR43","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/nature12506","volume":"500","author":"E Le Chatelier","year":"2013","unstructured":"Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, et al. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013;500(7464):541\u20136.","journal-title":"Nature"},{"issue":"7228","key":"657_CR44","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nature07540","volume":"457","author":"PJ Turnbaugh","year":"2009","unstructured":"Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, et al. A core gut microbiome in obese and lean twins. Nature. 2009;457(7228):480\u20134.","journal-title":"Nature"},{"issue":"9","key":"657_CR45","doi-asserted-by":"publisher","first-page":"e00232","DOI":"10.14309\/ctg.0000000000000232","volume":"11","author":"F Frost","year":"2020","unstructured":"Frost F, Weiss FU, Sendler M, Kacprowski T, R\u00fchlemann M, Bang C, et al. The gut microbiome in patients with chronic pancreatitis is characterized by significant dysbiosis and overgrowth by opportunistic pathogens. Clin Transl Gastroenterol. 2020;11(9):e00232.","journal-title":"Clin Transl Gastroenterol"},{"key":"657_CR46","doi-asserted-by":"publisher","first-page":"43640","DOI":"10.1038\/srep43640","volume":"7","author":"SM Jandhyala","year":"2017","unstructured":"Jandhyala SM, Madhulika A, Deepika G, Rao GV, Reddy DN, Subramanyam C, et al. Altered intestinal microbiota in patients with chronic pancreatitis: implications in diabetes and metabolic abnormalities. Sci Rep. 2017;7:43640.","journal-title":"Sci Rep"},{"issue":"2","key":"657_CR47","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1136\/gut.2005.073817","volume":"55","author":"C Manichanh","year":"2006","unstructured":"Manichanh C, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L, et al. Reduced diversity of faecal microbiota in Crohn\u2019s disease revealed by a metagenomic approach. Gut. 2006;55(2):205\u201311.","journal-title":"Gut"},{"key":"657_CR48","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.3389\/fmicb.2018.02247","volume":"9","author":"T Zuo","year":"2018","unstructured":"Zuo T, Ng SC. The gut microbiota in the Pathogenesis and therapeutics of inflammatory bowel disease. Front Microbiol. 2018;9:2247.","journal-title":"Front Microbiol"},{"issue":"1","key":"657_CR49","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1136\/gutjnl-2022-328166","volume":"72","author":"N Proch\u00e1zkov\u00e1","year":"2022","unstructured":"Proch\u00e1zkov\u00e1 N, Falony G, Dragsted LO, Licht TR, Raes J, Roager HM. Advancing human gut microbiota research by considering gut transit time. Gut. 2022;72(1):180\u201391.","journal-title":"Gut"},{"key":"657_CR50","unstructured":"Weiss S, Frost F. SHIP gut microbiome dataset for GP2 analysis; 2024."}],"container-title":["Gut Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13099-024-00657-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13099-024-00657-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13099-024-00657-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T20:31:24Z","timestamp":1729369884000},"score":1,"resource":{"primary":{"URL":"https:\/\/gutpathogens.biomedcentral.com\/articles\/10.1186\/s13099-024-00657-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,19]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["657"],"URL":"https:\/\/doi.org\/10.1186\/s13099-024-00657-1","relation":{},"ISSN":["1757-4749"],"issn-type":[{"value":"1757-4749","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,19]]},"assertion":[{"value":"3 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants provided written informed consent and the study was approved by the local ethics committee of the University Medicine Greifswald (BB 39\/08 and BB 122\/13).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dirk Roggenbuck is a shareholder of GA Generic Assays GmbH and Medipan GmbH. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"60"}}</enrichment>
    <enrichment key="opus_crossrefDocumentType">journal-article</enrichment>
    <enrichment key="opus_crossrefLicence">https://creativecommons.org/licenses/by/4.0</enrichment>
    <enrichment key="opus_import_origin">crossref</enrichment>
    <enrichment key="opus_doiImportPopulated">PersonAuthorFirstName_1,PersonAuthorLastName_1,PersonAuthorFirstName_2,PersonAuthorLastName_2,PersonAuthorFirstName_3,PersonAuthorLastName_3,PersonAuthorFirstName_4,PersonAuthorLastName_4,PersonAuthorFirstName_5,PersonAuthorLastName_5,PersonAuthorFirstName_6,PersonAuthorLastName_6,PersonAuthorFirstName_7,PersonAuthorLastName_7,PersonAuthorFirstName_8,PersonAuthorLastName_8,PersonAuthorFirstName_9,PersonAuthorLastName_9,PersonAuthorFirstName_10,PersonAuthorLastName_10,PersonAuthorFirstName_11,PersonAuthorLastName_11,PersonAuthorFirstName_12,PersonAuthorLastName_12,PersonAuthorFirstName_13,PersonAuthorLastName_13,PersonAuthorFirstName_14,PersonAuthorLastName_14,PersonAuthorFirstName_15,PersonAuthorLastName_15,PersonAuthorFirstName_16,PersonAuthorLastName_16,PersonAuthorFirstName_17,PersonAuthorLastName_17,PublisherName,TitleMain_1,Language,TitleAbstract_1,TitleParent_1,ArticleNumber,Issue,Volume,PublishedYear,IdentifierIssn,Enrichmentopus_crossrefLicence</enrichment>
    <enrichment key="BTU">an der BTU erstellt / created at BTU</enrichment>
    <enrichment key="Referiert">Beitrag ist referiert / Article peer-reviewed</enrichment>
    <enrichment key="opus.source">doi-import</enrichment>
    <enrichment key="opus.doi.autoCreate">false</enrichment>
    <enrichment key="opus.urn.autoCreate">false</enrichment>
    <author>
      <firstName>Fabian</firstName>
      <lastName>Frost</lastName>
    </author>
    <submitter>
      <firstName>Stefan</firstName>
      <lastName>Rödiger</lastName>
    </submitter>
    <author>
      <firstName>Stefan</firstName>
      <lastName>Weiss</lastName>
    </author>
    <author>
      <firstName>Johannes</firstName>
      <lastName>Hertel</lastName>
    </author>
    <author>
      <firstName>Malte</firstName>
      <lastName>Rühlemann</lastName>
    </author>
    <author>
      <firstName>Corinna</firstName>
      <lastName>Bang</lastName>
    </author>
    <author>
      <firstName>Andre</firstName>
      <lastName>Franke</lastName>
    </author>
    <author>
      <firstName>Matthias</firstName>
      <lastName>Nauck</lastName>
    </author>
    <author>
      <firstName>Marcus</firstName>
      <lastName>Dörr</lastName>
    </author>
    <author>
      <firstName>Henry</firstName>
      <lastName>Völzke</lastName>
    </author>
    <author>
      <firstName>Dirk</firstName>
      <lastName>Roggenbuck</lastName>
    </author>
    <author>
      <firstName>Peter</firstName>
      <lastName>Schierack</lastName>
    </author>
    <author>
      <firstName>Uwe</firstName>
      <lastName>Völker</lastName>
    </author>
    <author>
      <firstName>Georg</firstName>
      <lastName>Homuth</lastName>
    </author>
    <author>
      <firstName>Ali A.</firstName>
      <lastName>Aghdassi</lastName>
    </author>
    <author>
      <firstName>Matthias</firstName>
      <lastName>Sendler</lastName>
    </author>
    <author>
      <firstName>Markus M.</firstName>
      <lastName>Lerch</lastName>
    </author>
    <author>
      <firstName>Frank U.</firstName>
      <lastName>Weiss</lastName>
    </author>
    <collection role="institutes" number="2109">FG Multiparameterdiagnostik</collection>
  </doc>
</export-example>
